Bristol Myers Squibb (BMS) is an American pharmaceutical company, headquartered in New York City.
Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
BMS’ primary R&D sites are located in Lawrence, New Jersey (formerly Squibb, near Princeton), New Brunswick, New Jersey, and Redwood City, California; with other sites in Devens and Cambridge, Massachusetts, East Syracuse, New York, Braine-l’Alleud, Belgium, Tokyo, Japan, Bangalore, India and Wirral, United Kingdom. BMS previously had an R&D site in Wallingford, Connecticut (formerly Bristol-Myers).
The original firm, Clinton Pharmaceutical Co., was founded in Clinton, N.Y., in 1887 by William McLaren Bristol, Sr., and John R. Myers. It was incorporated as Bristol-Myers Company in 1900 and by then had moved from Clinton to Syracuse and then to Brooklyn. The company first made drugs for physicians, but after World War I it concentrated on the laxative Sal Hepatica and other over-the-counter proprietary drugs and entered the field of toiletries, notably with Ipana toothpaste. In 1929 Bristol-Myers was absorbed by a giant holding company, Drug Inc., which, however, dissolved during the Great Depression. Bristol-Myers became a publicly traded company in 1933.
In 1943 the company returned to its former emphasis on prescription drugs and diversified over the years by buying up a number of other companies, including a hair-care and cosmetics firm in 1959, a household-products manufacturer in 1965, and an infant-formula and nutrition company in 1967. In 1989 the merger of Bristol-Myers Company and Squibb Corporation—the descendant of a company founded by E.R. Squibb in 1858—created one of the world’s largest pharmaceutical companies.
To our patients and customers, employees, global communities, shareholders, environment and other stakeholders, we promise to act on our belief that the priceless ingredient of every product is the integrity of its maker. We operate with effective governance and high standards of ethical behavior. We seek transparency and dialogue with our stakeholders to improve our understanding of their needs. We take our commitment to economic, social and environmental sustainability seriously, and extend this expectation to our partners and suppliers.
To discover, develop and deliver innovative medicines that help patients prevail over serious diseases.